Global Circulating Tumor Cell Diagnostics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
- SKU ID : GIR-GIR1806220021 13050247
- |
- Publishing Date: 25-Oct-2018
- |
- Region: Global
- |
- No. of pages: 152
Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
Scope of the Report:
This report focuses on the Circulating Tumor Cell Diagnostics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Circulating Tumor Cell Diagnostics is expected to grow at a CAGR of roughly 9.2% over the next five years, will reach 8460 million US$ in 2023, from 4990 million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
CTC Enrichment
CTC Detection
CTC Analysis
Market Segment by Applications, can be divided into
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
There are 15 Chapters to deeply display the global Circulating Tumor Cell Diagnostics market.
Chapter 1, to describe Circulating Tumor Cell Diagnostics Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Circulating Tumor Cell Diagnostics, with sales, revenue, and price of Circulating Tumor Cell Diagnostics, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Circulating Tumor Cell Diagnostics, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Circulating Tumor Cell Diagnostics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Circulating Tumor Cell Diagnostics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
Scope of the Report:
This report focuses on the Circulating Tumor Cell Diagnostics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Circulating Tumor Cell Diagnostics is expected to grow at a CAGR of roughly 9.2% over the next five years, will reach 8460 million US$ in 2023, from 4990 million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
CTC Enrichment
CTC Detection
CTC Analysis
Market Segment by Applications, can be divided into
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
There are 15 Chapters to deeply display the global Circulating Tumor Cell Diagnostics market.
Chapter 1, to describe Circulating Tumor Cell Diagnostics Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Circulating Tumor Cell Diagnostics, with sales, revenue, and price of Circulating Tumor Cell Diagnostics, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Circulating Tumor Cell Diagnostics, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Circulating Tumor Cell Diagnostics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Circulating Tumor Cell Diagnostics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
